BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS [Yahoo! Finance]
Edesa Biotech, Inc. - Common Shares (EDSA)
Company Research
Source: Yahoo! Finance
This BARDA-funded project is expected to complement Edesa's ongoing drug development activities in COVID-19 ARDS. Paridiprubart was selected following a competitive review process of multiple host-directed therapeutic candidates. TORONTO, ON / ACCESSWIRE / June 24, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics (HDTs) for immuno-inflammatory diseases, announced today that its first-in-class drug candidate has been selected by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, for evaluation in a U.S. government-funded clinical study. Edesa's drug paridiprubart represents a new class of HDTs that are designed to modulate the body's own immune response when confronted with known or unknown public health threats such as pandemic influenza, COVID-19, other e
Show less
Read more
Impact Snapshot
Event Time:
EDSA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EDSA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EDSA alerts
High impacting Edesa Biotech, Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
EDSA
News
- Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc. [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc. [Yahoo! Finance]Yahoo! Finance
- Edesa Biotech, Inc. (NASDAQ: EDSA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.MarketBeat
- Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results [Yahoo! Finance]Yahoo! Finance
EDSA
Analyst Actions
- 8/20/24 - HC Wainwright
EDSA
Sec Filings
- 9/3/24 - Form 4
- 8/9/24 - Form 10-Q
- 8/9/24 - Form 8-K
- EDSA's page on the SEC website